GGrantIndex
← Search

Cancer Control and Survivorship (CCS) Research Program

$8,488P30FY2018CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

ABSTRACT ? CANCER CONTROL AND SURVIVORSHIP The Cancer Control and Survivorship (CCS) Program of the Robert H. Lurie Comprehensive Cancer Center (LCC) is a multidisciplinary program focusing on three specific aims: (1) Measurement Science: improve the measurement, analysis and interpretation of patient-reported outcomes (PROs); (2) Survivorship Research: improve cancer survivorship by studying biological, behavioral and sociocultural determinants of optimal survivorship; and (3) Intervention Development and Delivery: develop and implement targeted interventions to promote cancer control and reduce acute and long-term effects of cancer and related therapies. The Program is comprised of 32 faculty members from 13 departments and 3 schools. Total peer-reviewed funding is $10,236,948 (direct), with $3,769,564 from the NCI and $6,467,384 from other peer-reviewed sources. During calendar year 2016, a total of 975 participants were enrolled in program studies, with 313 enrolled in intervention studies and 662 enrolled in observational or correlative studies. During the current funding period there were 575 cancer-relevant publications, with 21% representing intra-programmatic collaborations, 29% representing inter-programmatic collaborations, and 88% representing inter-institutional collaborations. Over the current funding period, the CCS Program has made significant gains and its members have conducted high impact studies. For example, CCS members have developed and implemented brief, validated and clinically-relevant PRO measures, and identified contextual and modifiable factors associated with health-related quality of life (HRQoL) during survivorship. CCS members have also contributed to our understanding of neural substrates of the toxic effects of chemotherapy using fMRI techniques, documented adherence to quality metrics to improve surgical oncology outcomes, and developed and implemented fertility preservation techniques for cancer patients and survivors. Studies have also developed optimal processes for survivorship care within our clinics and across our community. Our work is grounded in measurement and intervention science discoveries made and psychosocial interventions to reduce cancer burden in our communities. The LCC provides significant value to the CCS Program by providing pilot funds and access to shared resources. In turn, the CCS program adds value to the LCC with strong program leadership, CCS Program meetings and speaker series, catchment- relevant and translational research, and by promoting collaborative opportunities that impact the LCC catchment area. The LCC and CCS leadership have developed a strategic plan to guide our future vision. The primary goal is to further strengthen our research across our aims by adding depth and breadth. Over the next 5 years, we will expand into cancer care delivery, precision oncology, pediatric survivorship, and dissemination and implementation science. We intend to renew our successful T32 grant; and develop PO1 submissions in prostate cancer and lifestyle factors in cancer survivors.

View original record on NIH RePORTER →